Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Current Deferred Revenue (2022 - 2025)

Dianthus Therapeutics has reported Current Deferred Revenue over the past 4 years, most recently at $954000.0 for Q3 2025.

  • Quarterly results put Current Deferred Revenue at $954000.0 for Q3 2025, up 854.0% from a year ago — trailing twelve months through Sep 2025 was $954000.0 (up 854.0% YoY), and the annual figure for FY2024 was $479000.0, changed.
  • Current Deferred Revenue for Q3 2025 was $954000.0 at Dianthus Therapeutics, up from $479000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for DNTH hit a ceiling of $954000.0 in Q3 2025 and a floor of $100000.0 in Q4 2022.
  • Median Current Deferred Revenue over the past 4 years was $100000.0 (2022), compared with a mean of $321222.2.
  • Biggest five-year swings in Current Deferred Revenue: changed 0.0% in 2024 and later skyrocketed 854.0% in 2025.
  • Dianthus Therapeutics' Current Deferred Revenue stood at $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then soared by 379.0% to $479000.0 in 2024, then skyrocketed by 99.16% to $954000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $954000.0 (Q3 2025), $479000.0 (Q2 2025), and $479000.0 (Q1 2025) per Business Quant data.